Lyka Labs Stock Screener | Share Price & Fundamental Analysis
LYKALABS
Pharmaceuticals
Screen Lyka Labs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹79.66
▼
-1.05 (-1.30%)
Share Price BSE
₹80.32
▼
-0.72 (-0.89%)
Market Cap
₹284.31 Cr.
P/E Ratio (TTM)
115.77
P/B Ratio
2.86
EPS (TTM)
₹2.22
Dividend Yield
-
Debt to Equity
0.55
52W High
₹159.87
52W Low
₹74.04
Operating Margin
12.00%
Profit Margin
5.88%
Revenue (TTM)
₹34.00
EBITDA
₹5.00
Net Income
₹2.00
Total Assets
₹176.00
Total Equity
₹104.00
Lyka Labs Share Price History - Stock Screener Chart
Screen LYKALABS historical share price movements with interactive charts. Analyze price trends and patterns.
Lyka Labs Company Profile - Fundamental Screener
Screen Lyka Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LYKALABS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE933A01014
Lyka Labs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen LYKALABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 176 | 157 | 152 | 186 | 190 | 200 | 216 | 229 | 252 | 242 |
| Current Assets | 67 | 51 | 44 | 52 | 29 | 36 | 35 | 49 | 63 | 82 |
| Fixed Assets | 85 | 58 | 68 | 94 | 98 | 105 | 108 | 116 | 133 | 104 |
| Liabilities | ||||||||||
| Total Liabilities | 176 | 157 | 152 | 186 | 190 | 200 | 216 | 229 | 252 | 242 |
| Current Liabilities | 26 | 51 | 73 | 73 | 165 | 149 | 85 | 9 | 42 | 30 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 104 | 68 | 46 | 14 | -25 | -15 | 46 | 53 | 45 | 49 |
| Share Capital | 36 | 33 | 31 | 29 | 29 | 29 | 28 | 28 | 22 | 23 |
| Reserves & Surplus | 68 | 26 | -3 | -15 | -55 | -43 | 14 | 21 | 16 | 22 |
Screen LYKALABS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34 | 34 | 38 | 28 | 31 | 41 | 35 | 23 | 23 | 28 | 33 | 36 | 28 | 27 | 19 |
| Expenses | 29 | 29 | 39 | 26 | 26 | 36 | 29 | 19 | 20 | 24 | 26 | 25 | 21 | 21 | 23 |
| EBITDA | 5 | 4 | -2 | 2 | 4 | 5 | 6 | 3 | 3 | 4 | 7 | 10 | 7 | 6 | -4 |
| Operating Profit % | 12.00% | 11.00% | -7.00% | 7.00% | 12.00% | 12.00% | 15.00% | 13.00% | 12.00% | 13.00% | 21.00% | 28.00% | 23.00% | 19.00% | -27.00% |
| Depreciation | 1 | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 4 | 4 | 3 | 10 | 4 | 4 | 4 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 3 | 1 | -4 | -2 | 2 | 3 | 4 | -3 | -2 | -1 | 3 | -2 | 1 | -1 | -10 |
| Tax | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 13 | 0 | 0 | 0 |
| Net Profit | 2 | 1 | -3 | -2 | 1 | 2 | 3 | -3 | -2 | -1 | 2 | -15 | 1 | 0 | -10 |
| EPS | 0.49 | 0.25 | -0.94 | -3.83 | 0.40 | 0.58 | 0.75 | -1.05 | -0.57 | -0.15 | 0.53 | -5.26 | 0.20 | -0.14 | -3.64 |
Lyka Labs Cash Flow Screener - Liquidity Fundamentals
Screen LYKALABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 2 | 2 | 9 | 79 | 9 | 5 | 27 | 11 | 31 | 12 |
| Investing Activities | -12 | -10 | 7 | -6 | 0 | 0 | -4 | -3 | -13 | 17 |
| Financing Activities | 5 | 2 | -22 | -63 | -12 | 3 | -23 | -10 | -19 | -30 |
| Net Cash Flow | -5 | -6 | -5 | 10 | -3 | 9 | -1 | -3 | 0 | -1 |
Screen LYKALABS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Apr | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 58.16% | 58.16% | 58.16% | 58.10% | 58.10% | 58.10% | 58.10% | 54.81% |
| FII Holding | 0.18% | 0.16% | 0.23% | 0.15% | 0.15% | 0.15% | 0.16% | 0.17% |
| DII Holding | 0.67% | 0.67% | 0.67% | 0.67% | 0.67% | 0.75% | 0.82% | 0.88% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.52% | 31.41% | 31.18% | 32.13% | 32.06% | 31.67% | 31.48% | 33.90% |
| Other Holding | 9.48% | 9.61% | 9.76% | 8.95% | 9.02% | 9.32% | 9.44% | 10.23% |
| Shareholder Count | 27,743 | 28,189 | 28,472 | 29,099 | 28,943 | 25,716 | 25,699 | 25,717 |
Lyka Labs Dividend Screener - Share Yield Analysis
Screen LYKALABS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Lyka Labs Index Membership - Market Screener Classification
Screen LYKALABS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Lyka Labs Market Events Screener - Corporate Actions
Screen LYKALABS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -3.01% |
| 2025-08-01 | 2025-08-01 | Annual General Meeting | NA | 4.21% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 1.70% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 5.18% |
| 2025-03-04 | 2025-03-04 | Extraordinary General Meeting | NA | -30.25% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -7.74% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 2.19% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 2.08% |
| 2024-02-20 | 2024-02-20 | Extraordinary General Meeting | NA | 9.92% |
| 2023-02-17 | 2023-02-17 | Extraordinary General Meeting | NA | -16.64% |
Lyka Labs Competitors Screener - Peer Comparison
Screen LYKALABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Lyka Labs Company Announcements - News Screener
Screen LYKALABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-30 | Closure of Trading Window | View |
| 2025-12-22 | Update On The Scheme Of Amalgamation | View |
| 2025-12-05 | Update On The Scheme Of Amalgamation | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-12 | Financial Results For The Quarter 30Th September 2025 | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 12Th November 2025 | View |
| 2025-11-08 | Update On The Scheme Of Amalgamation | View |
| 2025-10-23 | Board Meeting Intimation for Meeting To Be Held On 12Th November 2025 | View |
| 2025-10-11 | Update On Scheme Of Amalgamation | View |
| 2025-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Intimation Of Redemption Of Unlisted 10% Cumulative Redeemable Preference Shares | View |
| 2025-09-30 | Closure of Trading Window | View |
| 2025-09-29 | Board Meeting Outcome for Outcome Of The Board Meeting | View |
| 2025-09-24 | Board Meeting Intimation for Intimation Of The Board Meeting - 29Th September 2025 | View |
| 2025-09-18 | Update On The Scheme Of Amalgamation | View |
| 2025-09-05 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Updates | View |
| 2025-09-01 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-29 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-08 | Update On Scheme Of Amalgamation | View |